REFERENCES
1. Zhou X, Yu L, Zhao Y, Ge J. Panvascular medicine: an emerging discipline focusing on atherosclerotic diseases. Eur Heart J. 2022;43:4528-31.
2. Wong M, Dai Y, Ge J. Pan-vascular disease: what we have done in the past and what we can do in the future? Cardiol Plus. 2024;9:1-5.
3. Ruf B, Greten TF, Korangy F. Innate lymphoid cells and innate-like T cells in cancer - at the crossroads of innate and adaptive immunity. Nat Rev Cancer. 2023;23:351-71.
4. Imai T, Yoshida T, Baba M, Nishimura M, Kakizaki M, Yoshie O. Molecular cloning of a novel T cell-directed CC chemokine expressed in thymus by signal sequence trap using Epstein-Barr virus vector. J Biol Chem. 1996;271:21514-21.
6. Nakanishi T, Inaba M, Inagaki-Katashiba N, et al. Platelet-derived RANK ligand enhances CCL17 secretion from dendritic cells mediated by thymic stromal lymphopoietin. Platelets. 2015;26:425-31.
7. Catherine J, Roufosse F. What does elevated TARC/CCL17 expression tell us about eosinophilic disorders? Semin Immunopathol. 2021;43:439-58.
8. Stutte S, Quast T, Gerbitzki N, et al. Requirement of CCL17 for CCR7- and CXCR4-dependent migration of cutaneous dendritic cells. Proc Natl Acad Sci USA. 2010;107:8736-41.
9. Yan YH, Yu F, Zeng C, Cao LH, Zhang Z, Xu QA. CCL17 combined with CCL19 as a nasal adjuvant enhances the immunogenicity of an anti-caries DNA vaccine in rodents. Acta Pharmacol Sin. 2016;37:1229-36.
10. Schade DS, Shey L, Eaton RP. Cholesterol review: a metabolically important molecule. Endocr Pract. 2020;26:1514-23.
11. Minelli S, Minelli P, Montinari MR. Reflections on atherosclerosis: lesson from the past and future research directions. J Multidiscip Healthc. 2020;13:621-33.
13. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol. 2008;8:802-15.
14. Shortman K, Naik SH. Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol. 2007;7:19-30.
15. Weber C, Meiler S, Döring Y, et al. CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice. J Clin Invest. 2011;121:2898-910.
16. Imai T, Baba M, Nishimura M, Kakizaki M, Takagi S, Yoshie O. The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. J Biol Chem. 1997;272:15036-42.
17. Döring Y, van der Vorst EPC, Yan Y, et al. Identification of a non-canonical chemokine-receptor pathway suppressing regulatory T cells to drive atherosclerosis. Nat Cardiovasc Res. 2024;3:221-42.
18. Zhang Y, Tang X, Wang Z, et al. The chemokine CCL17 is a novel therapeutic target for cardiovascular aging. Signal Transduct Target Ther. 2023;8:157.
19. Raffort J, Lareyre F, Clément M, Hassen-Khodja R, Chinetti G, Mallat Z. Monocytes and macrophages in abdominal aortic aneurysm. Nat Rev Cardiol. 2017;14:457-71.
20. Ye Y, Yang X, Zhao X, et al. Serum chemokine CCL17/thymus activation and regulated chemokine is correlated with coronary artery diseases. Atherosclerosis. 2015;238:365-9.
21. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197-206.
22. Marchant DJ, Boyd JH, Lin DC, Granville DJ, Garmaroudi FS, McManus BM. Inflammation in myocardial diseases. Circ Res. 2012;110:126-44.
23. Feng G, Bajpai G, Ma P, et al. CCL17 aggravates myocardial injury by suppressing recruitment of regulatory T cells. Circulation. 2022;145:765-82.
24. Shi L, Li G, Hou N, et al. APOB and CCL17 as mediators in the protective effect of SGLT2 inhibition against myocardial infarction: Insights from proteome-wide mendelian randomization. Eur J Pharmacol. 2024;976:176619.
25. Schnelle M, Leha A, Eidizadeh A, et al. Plasma biomarker profiling in heart failure patients with preserved ejection fraction before and after spironolactone treatment: results from the aldo-DHF trial. Cells. 2021;10:2796.
26. Zhang Y, Ye Y, Tang X, et al. CCL17 acts as a novel therapeutic target in pathological cardiac hypertrophy and heart failure. J Exp Med. 2022:219.
27. Cheng P, Wang X, Liu Q, et al. LuQi formula attenuates Cardiomyocyte ferroptosis via activating Nrf2/GPX4 signaling axis in heart failure. Phytomedicine. 2024;125:155357.
28. Wang X, Liu Q, Cheng P, et al. LuQi formula ameliorates pressure overload-induced heart failure by regulating macrophages and regulatory T cells. Phytomedicine. 2025;141:156527.
29. Achim A, Péter OÁ, Cocoi M, et al. Correlation between coronary artery disease with other arterial systems: similar, albeit separate, underlying pathophysiologic mechanisms. J Cardiovasc Dev Dis. 2023;10:210.
30. Kollikowski AM, Schuhmann MK, Nieswandt B, Müllges W, Stoll G, Pham M. Local leukocyte invasion during hyperacute human ischemic stroke. Ann Neurol. 2020;87:466-79.
31. Alhadidi QM, Bahader GA, Arvola O, Kitchen P, Shah ZA, Salman MM. Astrocytes in functional recovery following central nervous system injuries. J Physiol. 2024;602:3069-96.
32. Giannoni P, Badaut J, Dargazanli C, et al. The pericyte-glia interface at the blood-brain barrier. Clin Sci. 2018;132:361-74.
33. Dargazanli C, Blaquière M, Moynier M, et al. Inflammation biomarkers in the intracranial blood are associated with outcome in patients with ischemic stroke. J Neurointerv Surg. 2025;17:159-66.
34. Farris BY, Monaghan KL, Zheng W, et al. Ischemic stroke alters immune cell niche and chemokine profile in mice independent of spontaneous bacterial infection. Immun Inflamm Dis. 2019;7:326-41.
35. Matsushita K, Ballew SH, Wang AY, Kalyesubula R, Schaeffner E, Agarwal R. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nat Rev Nephrol. 2022;18:696-707.
36. Anders HJ, Vielhauer V, Schlöndorff D. Chemokines and chemokine receptors are involved in the resolution or progression of renal disease. Kidney Int. 2003;63:401-15.
37. Furuichi K, Kaneko S, Wada T. Chemokine/chemokine receptor-mediated inflammation regulates pathologic changes from acute kidney injury to chronic kidney disease. Clin Exp Nephrol. 2009;13:9-14.
40. Lebherz-Eichinger D, Klaus DA, Reiter T, et al. Increased chemokine excretion in patients suffering from chronic kidney disease. Transl Res. 2014;164:433-43.e1.
41. Cox KJ, Parshall MB, Hernandez SHA, Parvez SZ, Unruh ML. Symptoms among patients receiving in-center hemodialysis: A qualitative study. Hemodial Int. 2017;21:524-33.
42. Spencer RH, Kilfeather SA, Lee E, et al. Systemic inflammatory markers correlate with chronic kidney disease-associated pruritus and response to treatment. J Invest Dermatol. 2026;146:175-83.e4.
43. Napolitano M, Fabbrocini G, Ruggiero A, Marino V, Nocerino M, Patruno C. The efficacy and safety of abrocitinib as a treatment option for atopic dermatitis: a short report of the clinical data. Drug Des Devel Ther. 2021;15:1135-47.
44. Thijs J, Krastev T, Weidinger S, et al. Biomarkers for atopic dermatitis: a systematic review and meta-analysis. Curr Opin Allergy Clin Immunol. 2015;15:453-60.
45. Li Y, Bonner MR, Browne RW, et al. Responses of serum chemokines to dramatic changes of air pollution levels, a panel study. Biomarkers. 2019;24:712-9.
46. Nukui Y, Yamana T, Masuo M, et al. Serum CXCL9 and CCL17 as biomarkers of declining pulmonary function in chronic bird-related hypersensitivity pneumonitis. PLoS One. 2019;14:e0220462.
47. Otsubo Y, Fujita Y, Ando Y, Imataka G, Yoshihara S. Elevated serum TARC/CCL17 levels associated with childhood interstitial lung disease with SFTPC gene mutation. Pediatr Pulmonol. 2022;57:1820-2.
48. Feng G, Zhu C, Lin CY, et al. CCL17 Protects against viral myocarditis by suppressing the recruitment of regulatory T cells. J Am Heart Assoc. 2023;12:e028442.
